Advancing Access to Digital Therapeutics
Spurred by significant investments, the digital therapeutics space has emerged into a fast-growing global market that is poised to reach more than $14.5 billion by 2028. Over the last five years, the U.S. Food and Drug Administration (FDA) has cleared more than 36 digital therapeutics across a number of therapeutic categories. Digital therapeutics – which diverge from other digital health tools, in part, because they are intended to prevent, manage, or treat a medical condition and must be cleared or certified by regulatory bodies to support claims of risk and efficacy – offer the potential to provide alternative, evidence-based treatment options for patients.
For the full article, please visit Fierce Pharma.